Publications → Themes → 06

Oncology

Long-tail safety questions in cancer and endocrine therapy where AsPEN's claims data captures real-world prescribing patterns that single-trial datasets miss — androgen deprivation, biologics, GLP-1–thyroid associations, and bone-targeting agents.

← Magazine view Full chronological list

3 papers · 2021–2022

2022 · Lancet Reg Health West Pac

Monoclonal antibodies and Fc-fusion protein biologic medicines: A multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010 and 2020

Tong X, Li X, Pratt NL, Hillen JB, Stanford T, Ward M, ..., Leung WK, Wong ICK.

biologicsaccessibilitymultinational 📄 Full text DOI: 10.1016/j.lanwpc.2022.100506 PMID: 35789824
2022 · BioDrugs

Comparative Treatment Persistence with Bone-Targeting Agents Among Asian Patients with Bone Metastases from Solid Tumors: A Multinational Retrospective Cohort Study

Shen CY, Au PC, Baek YH, Cheung CL, Chung WP, Kim JH, ..., Wong ICK, Lai ECC.

bone targetingoncologymultinational DOI: 10.1007/s40259-022-00528-8 PMID: 35412221
2021 · Cancers (Basel)

Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer

Liu JM, Shen CY, Lau WCY, Shao SC, Man KKC, Hsu RJ, Wu CT, Lai ECC.

androgen deprivationprostate cancerdementiamultinational 📄 Full text DOI: 10.3390/cancers13153861 PMID: 34359762